GlassScriptPhysician profile
Yasmin Akhunji
NPI 1790918738
$5,385.10
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $754 · 2021: $1,930 · 2022: $1,669 · 2023: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $850.33 | 2019-2022 | |
| Novo Nordisk INC | $645.87 | 2020-2023 | Wegovy |
| Lilly USA, LLC | $588.44 | 2019-2023 | Mounjaro, Trulicity, Humulin |
| Insulet Corporation | $486.58 | 2021-2022 | |
| Mannkind Corporation | $297.00 | 2019-2023 | Afrezza |
| Abbott Laboratories | $247.12 | 2020-2023 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $239.09 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $206.57 | 2019-2022 | |
| Dexcom, INC. | $185.60 | 2019-2022 | |
| Abbvie INC. | $176.25 | 2021-2023 | Synthroid |
| Embecta Corp. | $173.13 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Corcept Therapeutics | $157.37 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $121.63 | 2021-2023 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $120.59 | 2021-2023 | Unithroid |
| Alexion Pharmaceuticals, INC. | $117.09 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $100.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.12 | 2021-2022 | |
| Medtronic, INC. | $79.34 | 2021-2022 | |
| Radius Health, INC. | $66.07 | 2021 | |
| Clarus Therapeutics INC. | $57.03 | 2021 | |
| Merck Sharp & Dohme LLC | $51.28 | 2021-2022 | |
| Becton, Dickinson and Company | $44.00 | 2019-2022 | |
| Medtronic Minimed, INC. | $37.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $37.67 | 2022 | |
| Amgen INC. | $31.85 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $31.04 | 2022-2023 | |
| Intuity Medical INC | $26.57 | 2022 | |
| Lifescan, INC. | $19.30 | 2019 | |
| Alfasigma USA, INC. | $18.80 | 2021 | |
| Amarin Pharma, INC. | $15.29 | 2022 | |
| Medicure Pharma INC. | $14.94 | 2021 | |
| Currax Pharmaceuticals LLC | $14.53 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Akhunji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.